Literature DB >> 2313798

Clinical evidence for and implications of the multistep development of prostate cancer.

H B Carter1, S Piantadosi, J T Isaacs.   

Abstract

Based upon a large body of experimental and clinical data, it is evident that multiple malignant events are necessary for a normal cell to give rise to a fully malignant cancer cell. A critical issue with regard to human prostatic carcinogenesis is the clinical significance of the large number of cancers that are present histologically in the elderly male prostate gland. A possibility is that these histological prostate cancers already have undergone all of the malignant events necessary to produce clinically manifest cancer and, thus, only further tumor growth is required to produce a clinical tumor. Alternatively, these histological cancers may have undergone some but not all of the events necessary to produce clinical disease and, therefore, despite host longevity the cancer will remain clinically silent as long as no further malignant changes occur. This issue has importance clinically with respect to the diagnosis, therapy and possible prevention of prostatic cancer. Clinical observations and the mathematical relationship between prostate cancer prevalence and host age (time) support the fact that, in addition to growth, histological prostate cancer requires further malignant events to produce clinical disease. A better understanding of the events involved in prostate cancer development will be necessary to have a greater impact on this disease in the future.

Entities:  

Mesh:

Year:  1990        PMID: 2313798     DOI: 10.1016/s0022-5347(17)40078-4

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  34 in total

Review 1.  Krüppel cripples prostate cancer: KLF6 progress and prospects.

Authors:  Goutham Narla; Scott L Friedman; John A Martignetti
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

2.  System for MR image-guided prostate interventions: canine study.

Authors:  Robert C Susil; Axel Krieger; J Andrew Derbyshire; Attila Tanacs; Louis L Whitcomb; Gabor Fichtinger; Ergin Atalar
Journal:  Radiology       Date:  2003-09       Impact factor: 11.105

Review 3.  Dietary fat, fatty acids and prostate cancer.

Authors:  D P Rose; J M Connolly
Journal:  Lipids       Date:  1992-10       Impact factor: 1.880

4.  Prostate cancers in men with low PSA levels--must we find them?

Authors:  H Ballentine Carter
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

5.  Trends in cancer incidence, survival and mortality in northern Sweden 1960-1986.

Authors:  P Lenner; H Jonsson; O Gardfjell
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

Review 6.  Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening.

Authors:  Ruth Etzioni; Roman Gulati; Leslie Mallinger; Jeanne Mandelblatt
Journal:  Ann Intern Med       Date:  2013-06-04       Impact factor: 25.391

7.  Comparison between NK cell activity and prostate cancer stage and grade in untreated patients: correlation with tumor markers and hormonal serotest data.

Authors:  M Tarle; I Kraljić; M Kastelan
Journal:  Urol Res       Date:  1993-01

8.  Diagnosis, prognosis and management of incidentally found prostate cancer.

Authors:  P J Davidson
Journal:  Urol Res       Date:  1993-01

9.  Prostate cancer screening (United States).

Authors:  J W Waterbor; A J Bueschen
Journal:  Cancer Causes Control       Date:  1995-05       Impact factor: 2.506

10.  Prostate cancer in elderly men.

Authors:  Anton Stangelberger; Matthias Waldert; Bob Djavan
Journal:  Rev Urol       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.